Investors

Biostage has created a product that leading surgeons describe as, “revolutionary, “a breakthrough in tissue engineering and regenerative medicine” and that “would have considerable clinical use”.  - all quotes by top surgeons, from Massachusetts General Hospital, Mayo Clinic and Connecticut Children’s Medical Center.

Stock Information
OTCQBBSTG
Press Releases
Jan 12, 2023

Biostage removes Interim qualification from Mr. Green's title, making him Chief Executive Officer. HOLLISTON, Mass., Jan. 12, 2023 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the...

Dec 28, 2022

IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, Mass., Dec. 28, 2022 /PRNewswire/ -- Biostage, Inc....

Dec 23, 2022

Biostage expects to initiate patient recruitment in its first clinical trial in early 2023 HOLLISTON, Mass., Dec. 23, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the...

More >

Contact Us

Biostage, Inc.
84 October Hill Road
Suite 11
Holliston, Massachusetts 01746
United States

Phone: 774-233-7300
Toll Free: 855-209-3104
Fax: 774-233-7302

Investor Presentation

  
Download PDF

Fact Sheet